The Cooper Companies, Inc. (COO) Stock

The Cooper Companies, Inc. (COO) is a Healthcare stock trading at $70.64 (as of 2026-09-03), with a market capitalization of $13.78B and a trailing P/E of 58.4. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

The Cooper Companies, Inc. develops, manufactures, and markets vision and women’s health products through two segments: CooperVision, which offers contact lenses, and CooperSurgical, which provides medical devices and related services. These products are supplied to health care professionals and patients across regions including the Americas, Europe, Middle East, Africa, and Asia Pacific.

Understand The Cooper Companies, Inc.: how it makes money

Cooper makes contact lenses (spherical, toric, multifocal) for patients and family/women's health products for gynecologists and fertility clinics. The lens segment generates roughly twice the revenue of the surgical segment, and premium toric and multifocal products are the main growth lever.

Income is a recurring consumable: patients and clinics reorder lenses every 1 to 3 months, so revenue compounds with the aging myopia and presbyopia base rather than depending on a single product cycle.

Revenue by segment (latest quarter)
CooperVision$0.7B
CooperSurgical$0.4B
Other$0.0B

Business quality (Weak): Gross margin of 68% signals a strong moat in contact-lens formulation and regulatory approval, but the business quality grade is currently dragged to Weak by the one-time litigation hit and a P/E that sits well above the sector norm.

Valuation: At 52× earnings, COO trades 60% above the Medical Equipment average (33×).

Bull case

  • MySite fuels next growth wave: MySite delivered 24% growth in the quarter and is expanding into new geographies, giving Cooper a high-velocity digital channel layered on top of its existing optometrist distribution.
  • Fertility segment turning up: Management flagged that fertility trends are improving and expects continued back-half growth, which supports the CooperSurgical segment ($360M quarterly) beyond what the current run-rate implies.
  • 68% gross margin is structural: Gross margin held at 68% even with a $271.6M litigation charge in the quarter, confirming that the consumable-lens model carries strong pricing power and low material-cost leverage.

Bear case

  • Litigation hit is material: A $271.6 million net charge plus expected future payouts made operating margin negative (-3% this quarter). Until the legal overhang clears, free-cash-flow visibility is limited and the P/E multiple of 52.4x looks stretched.
  • Valuation far exceeds peers: At 52.4x trailing earnings versus the 33x Medical Equipment average, the stock already embeds 60% premium. Any miss on the MySite or fertility growth narrative would compress the multiple disproportionately.
  • Asia-Pac softness persists: Management warned that Asia-Pacific demand softness and hydrogel rationalization could extend through 2027, capping the geographic-growth story that underpins the premium multiple.
Valuation — source: SEC EDGAR (first-party)
Price$70.64
Market Cap$13.78B
P/E Ratio58.4
EV / EBITDA18.4
Price / Book1.67
Price / Sales3.26
FCF Yield3.1%
DCF Value (model)$6.19
DCF Upside vs Price-91.2%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$4.09B
Net Margin9.2%
Revenue Growth (YoY)7.9%
EPS Growth (YoY)-190.9%
FCF Growth (YoY)113.8%
Financial Health — source: SEC EDGAR
Altman Z-Score3.47 (safe)
Piotroski F-Score6/9 (moderate)
Valuation vs Sector & Industry
Stock P/E58.4
Sector P/E (Healthcare)21.6
Industry P/E (Medical Equipment)30.3
vs Sector170.5%
vs Industry92.5%
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($1.93B)
Institutional Holders Tracked10
Congressional Trades (recent)7
Company
SectorHealthcare
IndustryMedical Equipment
CEOAlbert G. White
Employees16,000
CountryUS
IPO Date1983-01-21

The Cooper Companies, Inc. earnings call transcripts

  • COO Q2 FY26 earnings call transcript (reported 2026-06-04) · analysis
  • COO Q1 FY26 earnings call transcript (reported 2026-03-05) · analysis
  • COO Q3 FY25 earnings call transcript (reported 2025-08-27) · analysis

All COO earnings calls

Related Companies (Medical Equipment; 8 comparable device makers)

  • Baxter International Inc. (BAX)
  • National Vision Holdings, Inc. (EYE)
  • Johnson & Johnson (JNJ)
  • AbbVie Inc. (ABBV)
  • Align Technology, Inc. (ALGN)
  • Mettler-Toledo International Inc. (MTD)
  • IDEXX Laboratories, Inc. (IDXX)
  • Illumina, Inc. (ILMN)
COO earnings history · COO institutional & insider holders · COO KPIs & operating metrics · COO financials · COO investor presentations & press releases · COO SEC filings · COO peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-09-03.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.